0VRQ Stock Overview
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
CRISPR Therapeutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.47 |
| 52 Week High | US$90.68 |
| 52 Week Low | US$36.55 |
| Beta | 1.67 |
| 1 Month Change | 8.76% |
| 3 Month Change | -0.51% |
| 1 Year Change | -43.03% |
| 3 Year Change | -19.62% |
| 5 Year Change | -7.76% |
| Change since IPO | 20.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VRQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.2% | -4.9% | -0.9% |
| 1Y | -43.0% | -16.3% | 9.8% |
Return vs Industry: 0VRQ underperformed the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0VRQ underperformed the UK Market which returned 9.8% over the past year.
Price Volatility
| 0VRQ volatility | |
|---|---|
| 0VRQ Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0VRQ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0VRQ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 393 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.
CRISPR Therapeutics AG Fundamentals Summary
| 0VRQ fundamental statistics | |
|---|---|
| Market cap | US$4.11b |
| Earnings (TTM) | -US$366.25m |
| Revenue (TTM) | US$37.31m |
110.1x
P/S Ratio-11.2x
P/E RatioIs 0VRQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VRQ income statement (TTM) | |
|---|---|
| Revenue | US$37.31m |
| Cost of Revenue | US$430.90m |
| Gross Profit | -US$393.59m |
| Other Expenses | -US$27.34m |
| Earnings | -US$366.25m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.27 |
| Gross Margin | -1,054.80% |
| Net Profit Margin | -981.54% |
| Debt/Equity Ratio | 0% |
How did 0VRQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 10:39 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CRISPR Therapeutics AG is covered by 45 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |